Pharmaceutical
Biopharmaceutical
Biotechnology

ImmunoGen

$1.93
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ImmunoGen and other stocks, options, ETFs, and crypto commission-free!

About

ImmunoGen, Inc. Common Stock, also called ImmunoGen, is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Read More Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.

Employees
296
Headquarters
Waltham, Massachusetts
Founded
1981
Market Cap
288.39M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
2.87M
High Today
$1.97
Low Today
$1.83
Open Price
$1.91
Volume
1.57M
52 Week High
$12.31
52 Week Low
$1.83

Collections

Pharmaceutical
Biopharmaceutical
Biotechnology
Therapy
Cancer Prevention
Technology
Health
US

News

Seeking AlphaMay 17

ImmunoGen: Assessing The Possibility Of A Turnaround

There is an aplenty of cash to fund its highly interesting pipeline. Other molecules have an excellent chance of delivering good results. Altogether, ImmunoGen is an excellent turnaround prospect to reward investors. With better endpoint guidance for positive results, I believe that the new investigation will bear excellent outcomes. After all, ImmunoGen now realized that mirvetuximab works best for high folate-alpha expression. ImmunoGen shares recently tumbled due to a negative regulatory binary. Amid t...

2,368
MarketWatchMay 16

ImmunoGen, Solid Biosciences and Insys lead Wednesday’s biotech losers

Shares of ImmunoGen Inc. led biotech’s losers on Wednesday, falling 38% in intraday trade after the company disclosed that the U.S. Food and Drug Administration had recommended it run a second Phase 3 trial of an ovarian cancer drug. A first Phase 3 trial of the biotech’s IMGN, +0.52% investigational drug, called mirvetuximab soravtansine, failed to show that patients on the therapy had better progression-free survival or overall survival than those on chemotherapy. Despite the disappointment, the company ...

44
Yahoo FinanceMay 15

ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer

WALTHAM, Mass.--(BUSINESS WIRE)-- Results to be Presented at 2019 ASCO Annual Meeting Combination Demonstrates Significant Anti-Tumor Activity and Favorable Safety and Tolerability in Platinum-Resistant Disease Scroll to continue with content Ad Findings Support Ongoing Studies of Doublet Combination in Platinum-Agnostic Disease and Triplet in Platinum-Sensitive Patients ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announ...

2,499

Earnings

-$0.37
-$0.28
-$0.19
-$0.10
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Jul 26, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.